SEC Form D private-offering filing
Biophytis SA
A new SEC Form D private-offering notice from Paris, a $1,584,275 filer-stated offering target in Biotech. The source filing is one click away.
Clinical-stage biotechnology company developing BIO101, a drug candidate for age-related diseases including sarcopenia and obesity, listed on Nasdaq and Euronext Growth Paris.
Filed 2026-03-23Filed to raise $1,584,275First money in 2026-03-13Raised so far $1,584,275HQ (as filed) ParisSector Biotech ✓Stage (inferred) SeedCall status Needs classification
Source linked the Form D on EDGAR↗Website verified biophytis.com↗Named in the filing 9 executives & directors
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.